Amarin Corp Plcuk (AMRN) Capital Expenditures Growth (3y) (2013 - 2026)
Amarin Corp Plcuk (AMRN) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 5.53% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 21.85% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -2.55% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 50.76% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 107.06% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 23.70% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 0.24% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -16.45% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -5.91% |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | 345.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 345.59% |
| Mar 31, 2026 | -28.07% |
| Mar 31, 2024 | -51.83% |
| Dec 31, 2023 | 66.04% |
| Sep 30, 2023 | -495.33% |
| Mar 31, 2023 | 30.36% |
| Sep 30, 2020 | 0.00% |
| Mar 31, 2020 | 68.92% |
| Dec 31, 2019 | -182.63% |
| Sep 30, 2019 | 34.54% |
| Mar 31, 2019 | 181.61% |
| Dec 31, 2018 | -62.91% |
| Sep 30, 2017 | 26.06% |
| Jun 30, 2017 | -7.74% |
| Mar 31, 2017 | 59.49% |
| Dec 31, 2016 | 27.25% |
| Mar 31, 2016 | -62.01% |
| Dec 31, 2015 | 26.12% |
| Sep 30, 2015 | -26.37% |
| Jun 30, 2015 | -27.12% |